Parkman Healthcare Partners’s Entera Bio ENTX Stock Holding History

Parkman Healthcare Partners’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$486K	Sell	274,497 -14,173	-5%	-$17.7K	0.05%	77
2026 Q1	$320K	Buy	288,670 +13,597	+5%	+$19.1K	0.03%	90
2025 Q4	$534K	Sell	275,073 -5,749	-2%	-$13.5K	0.05%	96
2025 Q3	$539K	Sell	280,822 -75,000	-21%	-$144K	0.06%	89
2025 Q2	$676K	Sell	355,822 -83,810	-19%	-$166K	0.08%	87
2025 Q1	$747K	Buy	439,632 +25,900	+6%	+$56.4K	0.09%	86
2024 Q4	$877K	Buy	413,732 +2,656	+0.6%	+$4.96K	0.12%	85
2024 Q3	$781K	Buy	411,076 +9,558	+2%	+$17K	0.1%	87
2024 Q2	$739K	Buy	+401,518	New	+$879K	0.1%	83

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Parkman Healthcare Partners's ENTX Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its Entera Bio (ENTX) stake by 4.9% in Q2 2026, selling an estimated $17.7K and leaving 274,497 shares worth $486K. The position accounts for 0.05% of the portfolio, ranked #77.

Parkman Healthcare Partners first reported a position in ENTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $877K in Q4 2024. 27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

Parkman Healthcare Partners held 274,497 shares of Entera Bio worth $486K as of Q2 2026.
Parkman Healthcare Partners sold 14,173 Entera Bio shares in Q2 2026, an estimated $17.7K.
Entera Bio made up 0.05% of Parkman Healthcare Partners's portfolio in Q2 2026, its #77 holding.
Parkman Healthcare Partners first reported a position in Entera Bio in Q2 2024 and has held it in 9 quarters since.
Parkman Healthcare Partners's Entera Bio position peaked at $877K in Q4 2024.
27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.